Based on research and analysis of the global microecology market, as well as the evaluation of relevant companies in the ...
The U.S. has been missing out on some of the world's best sunscreens, but we're finally getting bemotrizinol, and I'm excited ...
Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company ...
WPEC CBS 12 on MSN
FDA approves first oral treatments for gonorrhea in decades
For the first time in nearly 40 years, patients with uncomplicated urogenital gonorrhea have new oral treatment options.
The FDA has approved berotralstat oral pellets for prophylactic use in patients aged 2 to than 12 years with hereditary ...
The U.S. Food and Drug Administration has approved an oral pellet formulation of BioCryst Pharmaceuticals' drug to prevent hereditary angioedema attacks in children aged 2 to under 12, the company ...
BioCryst secures FDA approval for Orladeyo oral pellets, expanding preventive HAE therapy to children ages 2 to under 12.
Food and Drug Administration has expanded the use of BioCryst Pharmaceuticals' drug to include an oral pellet ...
The US Food and Drug Administration (FDA) agency is proposing to add bemotrizinol as a permitted active ingredient for use in ...
The U.S. Food and Drug Administration has approved an oral pellet formulation of BioCryst Pharmaceuticals' drug to prevent ...
Daybue Stix, a strawberry-flavored trofinetide powder mixable with water-based liquids, gains FDA approval for Rett syndrome treatment.
ESTERO, FL / ACCESS Newswire / December 4, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) (“Aspire” or the “Company”), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback